JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2002; 40:2125-2134
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davidson, M. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davidson, M. H.

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

Michael H. Davidson, MD, FACC*,*, Thomas McGarry, MD, FACC{dagger}, Robert Bettis, MD{ddagger}, Lorenzo Melani, MD, PhD§, Leslie J. Lipka, MD, PhD, FACC§, Alexandre P. LeBeaut, MD§, Ramachandran Suresh, PhD§, Steven Sun, PhD§, Enrico P. Veltri, MD, FACC§ Ezetimibe Study Group

* Chicago Center for Clinical Research, Chicago, Illinois, USA
{dagger} Oklahoma Foundation for Cardiovascular Research, Oklahoma City, Oklahoma, USA
{ddagger} Clinical Research Advantage, Edmonds Family Medicine Clinic, Edmonds, Washington, USA
§ Schering-Plough Research Institute, Kenilworth, New Jersey, USA



View larger version (29K):

[in a new window]
 
Figure 1 Study design. *Q1 = first qualifying LDL-C value using the Friedewald calculation; Q2 = second qualifying LDL-C value using the Friedewald calculation; blood samples for Q1 and Q2 were collected at least one week apart. {dagger}Randomization to double-blind treatment occurred at Visit 4. NCEP = National Cholesterol Education Program.

 


View larger version (22K):

[in a new window]
 
Figure 2 Percentage change in direct low-density lipoprotein cholesterol (A), high-density lipoprotein cholesterol (B), and triglyceride (C) concentrations from baseline to end point. EZE = ezetimibe; Simva = simvastatin. Nonfilled columns = Simva; filled columns = Simva + EZE. In (A), the asterisk denotes p < 0.01, combination versus statin alone.

 


View larger version (29K):

[in a new window]
 
Figure 3 Mean percent change from baseline in plasma concentration of direct low-density lipoprotein cholesterol (LDL-C) over time and at end point. EZE = ezetimibe; Simva = simvastatin.

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2002 by the American College of Cardiology Foundation.